IQ-AI Ltd

("IQ-AI" or the "Company")

Placing to raise £250,000

IQ-AI is pleased to announce that that the Company, through its corporate broker Peterhouse Capital Limited ("Peterhouse"), has conditionally raised gross proceeds of £250,000 via a placing (the "Placing") of 25,000,000 new ordinary shares at a price of £0.01 per share (the "Placing Shares"). The Placing was undertaken with existing and new shareholders.

Completion of the Placing is conditional on the Placing Shares being admitted to listing on the Equity Shares (transition) category of the Official List and to trading on the London Stock Exchange's main market for listed securities ("Admission").

Braveheart Investment Group plc ("Braveheart"), an existing shareholder in the Company, has subscribed for 7,000,000 Placing Shares for a consideration of £70,000. On Admission of the Placing Shares, Braveheart will hold 72,415,862 ordinary shares in IQ-AI which represents 29.35% of the issued share capital of IQ-AI as enlarged by the Placing.

Use of Proceeds

The proceeds will be used for clinical trials of GaM (adult and pediatric) and the Expanded Access Program. Additionally, the funds will support and accelerate organic growth, including the completion of the release of IB Clinic and IB Nimble, as well as the expansion of the marketing and sales teams.

Admission & Total Voting Rights ("TVR") Statement

Prior to this Placing, the Company had 221,709,789 ordinary shares of £0.01 par value on issue, each with one vote per share. The Company does not hold any ordinary shares in treasury. Following the issuance of the 25,000,000 Placing Shares, the TVR will increase by 25,000,000 shares, bringing the total number of voting rights in the Company to 246,709,789.

Therefore, the figure of 246,709,789, post the issue of these new Placing Shares, can be used by shareholders to determine whether they have a notifiable interest in the share capital of the Company under the Disclosure Guidance and Transparency Rules, or if such interest has changed.

Applications will be made to the FCA and to the London Stock Exchange for admission in respect of all the Placing Shares proposed to be issued on completion of the Placing.  It is expected that Admission will become effective, and that dealings in the Placing Shares are expected to commence at 8.00 a.m. 24 March 2025.

The rights attaching to the Placing Shares will be uniform in all respects and all of the new Placing Shares will rank pari passu, and form a single class for all purposes with, the existing issued shares of £0.01 in the Company.

--ENDS--

 The Directors of the Company accept responsibility for the contents of this announcement.

 For further information, please contact:

About Imaging Biometrics, LLC

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.